2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

Reports Q4 revenue $2.9M, consensus $13.03M. “2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure and focus solely on Abecma,” said Chip Baird, chief executive officer, 2seventy bio (TSVT). “This week marks four years since Abecma received FDA approval as the first anti-BCMA CAR T cell therapy approved for relapsed or refractory multiple myeloma. Together with BMS, we remain committed to expanding the reach of this important therapy. We launched 2seventy with the goal of providing more time to patients, and we believe with BMS’ experience and resources, we can continue to improve outcomes for people living with multiple myeloma.”